Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Clinical and Pathological Benefits of Photobiomodulation – Archive

Webinar Credits: 1.5

Join these experts from around the globe as they discuss the impact of dry age-related macular degeneration (AMD) and geographic atrophy (GA), the limitations of currently available treatments, and how novel therapies under investigation may have the potential to improve vision and quality of life for patients with dry AMD and GA.

Expiration Date: Wednesday, October 20, 2021
Release Date: October 23, 2020

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the incidence and impact of dry age-related macular degeneration (AMD).
  • Discuss disease management options for patients with dry AMD and geographic atrophy.
  • Explain and compare the treatments currently under investigation for dry AMD, including photobiomodulation, gene therapy, and other novel approaches.
  • Summarize the mechanisms of action of the dry AMD investigative therapies and their potential application to other disease states.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the European Union of Medical Specialties (UEMS). Following the agreement on the mutual recognition of credits between the AMA and the UEMS-European Accreditation Council for CME, European physicians can earn ECMECs® by completing e-learning programs from accredited providers that have been certified for AMA PRA Category 1 Credits™.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Faculty:


Praveen R. Arany, BDS, MDS, MMSc, PhD
Assistant Professor, Oral Biology & Biomedical Engineering
School of Dental Medicine, Engineering & Applied Sciences
University at Buffalo
Buffalo, New York

 


Janis T. Eells, PhD
Professor, Biomedical Sciences
College of Health Sciences
Adjunct Professor, Epidemiology
Joseph J. Zilber School of Public Health
University of Wisconsin-Milwaukee
Milwaukee, Wisconsin

 


Samuel N. Markowitz, MD, FRCSC
Professor of Ophthalmology and Vision Sciences
Faculty of Medicine
Director, Low Vision Rehabilitation Program
Department of Ophthalmology
University of Toronto
Clinician Investigator
The Krembil Research Institute
Staff, Toronto Western Hospital
Toronto, Ontario

 


Marion R. Munk, MD, PhD
Department of Ophthalmology
University Hospital of Bern
Bern, Switzerland

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Praveen R. Arany, BDS, MDS, MMSc, PhD and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speakers Bureau: Thor Phtomedicine, LumiThera, Weber Medical. Consultant: Kerber Applied Research, Vielight, Curalse, NeoMedLight, Scarborough, Joovv, MuReva. Grant/Research Support: Philips Research, NST Consulting, NIDCR, NIG, Goldwave. Stock/Shareholder: Optimed Technology

Janis T. Eells, PhD and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support, Consultant, Speaker’s Bureau, Stock/Shareholder: LumiThera, Inc

Samuel N. Markowitz, MD, FRCSC and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support, Speaker’s Bureau, Stock/Shareholder: LumiThera, Inc

Marion R. Munk, MD, PhD and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Bayer. Consultant: LumiThera, Zeiss, Novartis, Bayer, Allergan, Gensight Therapeutics, RetinAl. Speaker’s Bureau: Zeiss, LumiThera

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or  LumiThera.

Pretest

  • a. 1b. 2c. 3d. 4e. 5

Video Resources

Next

Test

Instructions

Step 1 of 2

  • a. 1b. 2c. 3d. 4e. 5
  • AgreeNeutralDisagree
    Describe the incidence and impact of dry age-related macular degeneration (AMD).
    Discuss disease management options for patients with dry AMD and geographic atrophy.
    Explain and compare the treatments currently under investigation for dry AMD, including photobiomodulation, gene therapy, and other novel approaches.
    Summarize the mechanisms of action of the dry AMD investigative therapies and their potential application to other disease states.
Back